TESSALON Drug Patent Profile

« Back to Dashboard

When do Tessalon patents expire, and what generic alternatives are available?

Tessalon is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in TESSALON is benzonatate. There is one drug master file entry for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the benzonatate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tessalon

A generic version of TESSALON was approved as benzonatate by BIONPHARMA on January 29^th, 1993.

Summary for TESSALON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	62
Patent Applications:	2,642
Drug Prices:	Drug price information for TESSALON
What excipients (inactive ingredients) are in TESSALON?	TESSALON excipients list
DailyMed Link:	TESSALON at DailyMed

See drug prices for TESSALON

US Patents and Regulatory Information for TESSALON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TESSALON	benzonatate	CAPSULE;ORAL	011210-001	Approved Prior to Jan 1, 1982	AA	RX	Yes	No
Pfizer	TESSALON	benzonatate	CAPSULE;ORAL	011210-003	Jun 25, 1999		DISCN	Yes	No

Tessalon Market Dynamics and Financial Trajectory: Benzonatate Exclusivity, Competition, and Revenue Outlook

Last updated: October 16, 2026

Tessalon is the legacy brand for benzonatate, a prescription, non-opioid antitussive sold primarily as 100 mg and 200 mg liquid-filled capsules. Its commercial profile is defined by generic competition, seasonal demand, limited brand differentiation, and the absence of meaningful remaining market exclusivity. Tessalon has no publicly reported standalone revenue stream, and the commercially relevant market is the broader U.S. benzonatate market rather than the legacy brand alone.

What is Tessalon and how does benzonatate generate demand?

Tessalon contains benzonatate, a peripherally acting cough suppressant that anesthetizes stretch receptors in the respiratory passages, lungs, and pleura. The FDA-approved product is indicated for the symptomatic relief of cough in patients older than 10 years. Tessalon is administered orally in 100 mg or 200 mg capsules, which must be swallowed whole because chewing or dissolving the capsule can cause oral and airway anesthesia [1].

Benzonatate demand is driven by:

• Acute cough associated with viral respiratory infections
• Seasonal influenza and common-cold activity
• Outpatient prescribing by primary-care physicians and urgent-care clinics
• Patient preference for a non-opioid prescription cough suppressant
• Continued use when dextromethorphan or codeine-containing products are unsuitable

The product does not treat the underlying cause of cough. Its role is symptomatic, which limits pricing power and reduces the likelihood of durable brand loyalty.

What is the FDA regulatory status of Tessalon?

Tessalon is an FDA-approved prescription drug, not an over-the-counter medicine. Benzonatate received its initial U.S. approval in 1958, placing it among the older prescription products still used in outpatient care [1].

Regulatory attribute	Tessalon / benzonatate status
Active ingredient	Benzonatate
Dosage form	Liquid-filled oral capsule
Common strengths	100 mg and 200 mg
FDA pathway	Original NDA and subsequent ANDA generic approvals
Prescription status	Rx-only
Initial U.S. approval	1958
Therapeutic category	Antitussive
Biosimilar relevance	None
Current exclusivity profile	No commercially meaningful regulatory exclusivity
Primary market structure	Generic prescription market

The product has been subject to FDA safety communications and labeling emphasis concerning accidental ingestion, particularly in children. A small number of capsules can produce serious toxicity in pediatric patients. Reported reactions include oral numbness, choking, laryngospasm, seizures, cardiac arrhythmias, and death [2].

These safety risks affect prescribing, dispensing instructions, and liability exposure. They do not create market exclusivity.

When does Tessalon lose patent and regulatory exclusivity?

Tessalon’s original product protection expired decades ago. The 1958 approval date places the product outside the commercial life of any original compound or formulation patent that could support current exclusivity.

The relevant commercial facts are:

Exclusivity category	Current implication
New chemical entity exclusivity	Expired
Original product patent protection	Expired
Pediatric exclusivity	No current commercial relevance
Orphan-drug exclusivity	Not applicable
New formulation exclusivity	No widely recognized protection supporting the core market
Method-of-use exclusivity	No material barrier to routine generic prescribing
Generic competition	Established
180-day Paragraph IV launch barrier	Not a current structural feature of the market

Tessalon is therefore an off-patent product. Generic manufacturers can compete through abbreviated new drug applications, subject to FDA approval and applicable product-quality requirements.

How many patents cover Tessalon and benzonatate?

No meaningful active patent estate is associated with the core Tessalon product. The commercial opportunity rests on manufacturing, distribution, supply reliability, and pharmacy contracting rather than patent protection.

Potentially relevant intellectual-property categories include:

1. Capsule composition and soft-gel manufacturing methods.
2. Packaging and child-resistant delivery systems.
3. Alternative dosage forms.
4. Combination cough-and-cold products.
5. Manufacturing process know-how.

These categories can create operational advantages but are unlikely to block ordinary generic benzonatate capsules. A manufacturer would generally face a low patent barrier when entering the standard 100 mg or 200 mg capsule market.

What is the Orange Book status of Tessalon?

The Orange Book is relevant because it identifies FDA-approved drug products and patent certifications associated with listed products. For an old, genericized product such as benzonatate, the commercial question is not whether the original Tessalon brand remains protected. It is whether any currently listed patent or exclusivity period blocks an ANDA applicant.

The core Tessalon market has no evident Orange Book-based exclusivity barrier. FDA-listed generic products compete through ANDAs, and the principal market constraint is approval and commercial execution rather than patent clearance [3].

The absence of a strong Orange Book position has several effects:

• Generic entry is legally routine.
• Paragraph IV litigation is unlikely to be a central market event.
• Brand substitution is structurally easy.
• Pricing pressure increases as additional suppliers enter.
• A manufacturer cannot rely on patent-based premium pricing.

Which companies compete with Tessalon?

Competition occurs at two levels: branded or legacy Tessalon products and generic benzonatate.

Generic benzonatate manufacturers

The U.S. market has included multiple generic suppliers over time, including companies such as Amneal Pharmaceuticals, Aurobindo Pharma, Cipla, KVK-Tech, and other ANDA holders or contract-manufacturing participants. Supplier participation can change as approvals, discontinuations, shortages, and commercial decisions alter the market.

The most important competitive variables are:

• FDA approval status
• Manufacturing capacity
• Softgel quality and defect rates
• Wholesale acquisition cost
• Pharmacy benefit-manager contracting
• Distributor access
• Ability to maintain supply during respiratory-virus surges

The brand name “Tessalon” has limited defensive value when pharmacies can dispense therapeutically equivalent benzonatate at lower cost.

Therapeutic substitutes

Benzonatate competes with:

• Dextromethorphan
• Guaifenesin combinations
• Codeine-containing cough products
• Hydrocodone-containing antitussives
• Honey and other nonprescription remedies
• Treatment of the underlying condition rather than cough suppression

Dextromethorphan is a major substitute because it is widely available over the counter and has strong consumer recognition. Opioid-containing antitussives face tighter regulatory controls and safety concerns, which can support benzonatate use in selected prescriptions.

What market dynamics affect Tessalon sales?

Seasonal demand

Benzonatate volumes typically rise during periods of increased respiratory illness. Prescribing can accelerate during influenza, respiratory syncytial virus, and broader viral upper-respiratory infection waves. This produces a seasonal revenue pattern rather than a stable, chronic-therapy profile.

Seasonality creates inventory-management risk. Manufacturers must balance:

• Higher demand during winter respiratory seasons
• Lower utilization during warmer months
• Short product shelf life relative to long-term inventory planning
• Distribution capacity
• Potential short-term shortages

Generic price erosion

The core product has low clinical differentiation and multiple suppliers. This typically produces declining prices over the product life cycle. Price erosion may be interrupted by supply disruptions, manufacturing exits, or temporary demand spikes, but those events generally benefit suppliers with available inventory rather than the legacy brand.

Prescription-only positioning

Benzonatate retains an advantage over opioid antitussives because it is non-opioid and does not carry the same controlled-substance framework. It lacks the convenience and broad consumer reach of OTC dextromethorphan, however. Its Rx-only status limits direct consumer demand generation and makes prescribing behavior central to market performance.

Safety-related demand constraints

The FDA has highlighted the risk of serious adverse events from accidental ingestion and improper administration. The requirement to swallow capsules whole is especially important. These warnings can constrain pediatric use, reduce physician willingness to prescribe in households with young children, and increase pharmacy counseling requirements [2].

What are the financial prospects for Tessalon?

Tessalon does not appear to have a separately disclosed revenue line in public financial reporting. The legacy brand is not treated as a material standalone product in the filings of major pharmaceutical companies. As a result, a precise brand-level revenue trajectory cannot be derived from public issuer disclosures.

The financial trajectory is better characterized as follows:

Period	Financial profile
Early commercial period	Protected or semi-protected branded prescription product
Generic-entry period	Rapid substitution and price compression
Mature market	Low-margin, volume-driven generic product
Demand surge periods	Temporary volume and pricing improvement
Long-term outlook	Stable but modest category revenue, subject to generic competition

Revenue is concentrated in the aggregate benzonatate market, not in Tessalon-branded sales. The economic value for generic manufacturers comes from scale, low manufacturing cost, reliable supply, and efficient distribution.

Revenue exposure for manufacturers

Benzonatate is unlikely to be a material revenue driver for diversified pharmaceutical companies. It may have greater importance for:

• Small generic manufacturers with concentrated portfolios
• Contract manufacturers with softgel capacity
• Distributors during supply shortages
• Companies using benzonatate as part of a broader respiratory portfolio

The product’s low average selling price limits absolute revenue potential. A supplier can still generate attractive contribution margins if it has efficient production and avoids quality failures, but the market does not support high-margin branded economics.

What manufacturing and intellectual-property barriers affect benzonatate?

The main barriers are operational rather than legal.

Softgel manufacturing

Benzonatate is commonly supplied as a liquid-filled capsule. Softgel manufacturing requires control over:

• Active-ingredient dispersion
• Fill-weight uniformity
• Capsule-shell integrity
• Leakage and brittleness
• Dissolution performance
• Packaging stability

A company with approved softgel capacity can have an advantage over a nominally approved supplier that lacks dependable commercial production.

Quality and supply continuity

Quality problems can produce product recalls, wholesaler delisting, or FDA scrutiny. Because benzonatate is inexpensive, manufacturers may have limited financial room to absorb repeated remediation costs.

Supply continuity can create short-term pricing power. That advantage is usually temporary because other ANDA holders can expand shipments when commercially attractive.

Patent barriers

No major patent barrier appears to protect standard benzonatate capsules. Process know-how may be valuable, but it generally does not prevent competing manufacturers from supplying an equivalent FDA-approved product.

What patent litigation, Paragraph IV challenges, or settlements affect Tessalon?

Tessalon has no prominent current litigation profile comparable to newer branded drugs with active compound, formulation, or method-of-use patents. The product’s age and established generic competition reduce the likelihood that a new Paragraph IV dispute would materially reshape the market.

The relevant legal position is:

• No active core patent estate drives exclusivity.
• Generic entry has already occurred.
• No major settlement structure controls broad market access.
• Litigation risk is more likely to involve product liability, manufacturing quality, labeling, or commercial disputes than patent exclusivity.

Product liability remains a commercial consideration because accidental ingestion and improper capsule administration can cause severe outcomes. Those risks can affect insurers, manufacturers, distributors, and pharmacy protocols even when they do not alter market share directly.

How does Tessalon compare with dextromethorphan and opioid cough medicines?

Attribute	Tessalon / benzonatate	Dextromethorphan	Codeine or hydrocodone antitussives
Prescription status	Prescription	Mostly OTC	Prescription
Opioid	No	No	Yes
Generic competition	High	High	High
Consumer recognition	Moderate	High	Moderate
Patent protection	None of commercial significance	Generally mature	Mature
Pediatric safety concern	Serious accidental-ingestion risk	Abuse and dosing concerns	Respiratory depression and misuse
Pricing power	Low	Low	Higher in some channels
Main demand driver	Prescriber selection and respiratory season	Consumer and OTC demand	Selected prescription use

Benzonatate occupies a middle position. It has the prescription positioning of opioid cough medicines without being an opioid, but it lacks the OTC convenience and consumer familiarity of dextromethorphan.

What generic launch scenarios exist for Tessalon?

Base case: stable generic market

Multiple suppliers remain active, prices stay low, and demand follows respiratory-season patterns. This is the most likely long-term scenario.

Upside case: supply-constrained pricing

A manufacturing interruption, product recall, or supplier exit reduces available inventory. Remaining suppliers may gain volume and temporarily improve pricing.

Downside case: substitution and lower prescribing

Physicians increasingly use OTC products, avoid benzonatate because of pediatric safety concerns, or treat cough through management of the underlying condition. Volumes decline while generic price competition continues.

Commercial expansion case

A supplier obtains stronger distribution, expands hospital and urgent-care contracts, or packages benzonatate within a respiratory portfolio. This can improve a company’s share without changing the overall market’s low-exclusivity structure.

Key Takeaways

• Tessalon is the legacy brand for benzonatate, a prescription non-opioid cough suppressant.
• The product received initial U.S. approval in 1958 and has no meaningful remaining compound or formulation exclusivity.
• Generic competition, not patent protection, determines market economics.
• The market is seasonal, price-sensitive, and dependent on reliable softgel manufacturing.
• Tessalon does not have publicly disclosed standalone revenue that supports a precise brand-level financial forecast.
• The broader benzonatate market is likely to remain a modest, mature generic category.
• Short-term revenue upside is most likely during respiratory-virus surges or supply disruptions.
• Safety risks involving accidental ingestion and capsule chewing remain important commercial and regulatory constraints.
• Paragraph IV litigation and patent settlements are not central current drivers of the market.
• The principal investment question is supplier execution, not patent strength.

FAQs

Is Tessalon still a profitable drug?

Tessalon is unlikely to support branded-drug profitability because generic substitution and low pricing have eroded its economic value. Profitability may remain attractive for efficient generic manufacturers with dependable softgel capacity.

Is benzonatate protected by a patent?

The core benzonatate product is not protected by a commercially meaningful active patent estate. Manufacturing know-how and packaging technology may provide operational advantages but generally do not block generic entry.

Can a generic manufacturer launch benzonatate without a Paragraph IV lawsuit?

Yes. Because the core product is mature and genericized, an ANDA applicant can generally pursue approval without confronting the type of active patent barrier associated with newer branded drugs.

Does Tessalon have biosimilar competition?

No. Tessalon contains a small-molecule active ingredient, benzonatate. Biosimilar regulation applies to biologic products, not to this capsule product.

What is the biggest commercial risk for benzonatate manufacturers?

The largest risks are generic price erosion, seasonal demand volatility, softgel manufacturing failures, product recalls, and safety-related liability involving accidental ingestion or improper administration.

References

1. U.S. Food and Drug Administration. (2010). Tessalon (benzonatate) capsules prescribing information. FDA.
2. U.S. Food and Drug Administration. (2010). FDA drug safety communication: Benzonatate overdose risk in children younger than 10 years. FDA.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.